Mylan says Sanofi loses Lantus insulin patent claims 2 Min Read (Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi’s infringement claims relating to insulin drug Lantus. Sanofi is heavily reliant on Lantus, its leading product with sales of 4.62 billion euros ($5.26 billion) in 2017, and Mylan’s own insulin drug would be its second competitor after Eli Lilly launched its version in late 2016. Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and paediatric patients with type 1 diabetes to control high blood sugar. https://www.reuters.com/article/us-...tus-patent-claims-against-mylan-idUSKBN1OC1MN